Supplementary Figure S10 : OSU-2S is active in leukemic mouse models of CLL.
Supplementary Table 1 : Characterization of OSU-2S-LP and 2A2-OSU-2S-ILP.
Supplementary Table 2 : ROR1 expression by microarray (gene expression) and flowcytometry (cell surface) on CLL cells after OSU-2S treatment.
Supplementary Table 3 : CD19 and CD20 cell surface expression on CLL cells after OSU-2S treatment.
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Supplementary Methods:
Immunoblotting:
Cells were lysed with lysis buffer containing 10mM Tris (tris(hydroxymethyl)aminomethane) pH 7.4, 150mM sodium chloride, 1% Triton X-100, 1% deoxycholic acid, 10% SDS and 5mM
EDTA. Cytoplasmic and nuclear extracts were prepared with NE-PER extraction kit (Pierce, Thermo scientific, Rockford, IL). Proteins were quantified by bicinchoninic acid (BCA) method (Pierce), separated by SDS-PAGE gel, transferred to nitrocellulose membrane (Schleicher & Schuell, Keene, NH). The blots were probed with commercially obtained indicated antibodies, followed by horseradish peroxidase (HRP) conjugated secondary antibodies (Bio-Rad Laboratories, Hercules, CA) and detected by addition of chemiluminescent substrate (Pierce).
Quantification was done with Chemi-Doc system with Quantity one software (Bio-Rad Laboratories, Hercules, CA).
Phosphatase assay:
SHP1 and PP2A enzyme activity were measured using DuoSet®IC (R&D Systems, Minneapolis, MN) and PP2A immunoprecipitation phosphatase assay kit (Upstate/Millipore, Billerica, MA) respectively as per manufacturer's instructions. In brief, phosphatase enzymes were immunoprecipitated from CLL cell extracts using anti-SHP1/PP2A antibody conjugated/and agarose beads and incubation of enzyme bound beads with phospho peptide substrate to release free phosphate, followed by detection using malachite green solution and molybdic acid. The phosphatase activity is expressed as amount of free phosphate released from the reaction normalized to the levels of enzyme immunoprecipitated as quantified by immunoblotting to avoid variability in immunoprecipitation across the samples.
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Immunoprecipitation:
Immunoprecipitation was carried out by incubating cell lysates with primary antibody and protein A agarose beads (Millipore, Billerica, MA) in Tris buffered saline-tween20 (TBST)
overnight at 4°C in a rocker, followed by washing the beads 6 times with ice cold TBST. The beads were boiled with Laemmeli buffer before separation by SDS-PAGE.
Confocal fluorescence microscopy: 
In-vivo experiments:
All animal experiments were carried out under protocols approved by The Ohio State University
Institutional Animal Care and Use Committee (IACUC). C57BL/6 animals (Taconic Farm, Germantown, NY) were used for immunosuppressive studies comparing FTY720 and OSU-2S.
Eµ-TCL1 mice 1 with white blood cell (WBC) count >15 x 10 3 /µl were used for cytoreduction studies. Animals meeting the criterion de-novo were grouped into Vehicle or OSU-2S and received three daily doses (5mg/kg) of treatment and were bled to assess WBC count by staining peripheral blood smear. CD19 and CD3 percentages were analyzed by flowcytometer after RBC depletion.
Eµ-ROR1-TCL1 mouse engraftment studies were done by injecting 10x10 6 splenocytes isolated from Eµ-ROR1-TCL1 double transgenic animal with known frank leukemia and splenomegaly into Eµ-ROR1 single transgenic mouse by tail vein injection for leukemia adaptation. Upon confirmation of leukemia as evidenced by circulating CD5+CD19+ cells and splenomegaly, the splenic cells were engrafted into syngenic C57BL/6 animals. Splenocytes isolated by ficoll
Supplementary Page 6 density centrifugation were stained for B220, CD5, hROR1 expression and viability and about 10x10 6 cells were injected into tail vein of C57BL/6 recipient and the disease progression was monitored bi-weekly by flowcytometric analysis of peripheral blood. Animals that have developed high WBC count (>10x10 3 /µl) and 5% B220+CD5+ leukemic cells in peripheral blood were grouped into treatment groups and dosed 10 mg/kg everyday by intra-peritoneal injection of ILP formulations. All animals were monitored for signs of disease and other early removal criteria, including greater than 20% weight loss or cancer induced cachexia, inability to feed or move around and other infections.
Eµ-ROR1 transgenic mice generation:
A 3.5kb Not1 human ROR1hROR1 cDNA fragment from pCMV6-XL6 plasmid (kindly provided by Christoph Rader, NCI) was cloned into the Bgl2 site of the pBH vector that was
shown to direct B cell specific expression of transgenes. 2, 3 Expression of hROR1 was confirmed in 70/z3 mouse pre-B cell lines transfected with the above construct containing hROR1 cDNA.
Transgenic mice were generated by pronuclear injection of about 6.5kb fragment released with Not1/Kpn1 from the pBH transgenic construct in fertilized oocytes from C57BL/6 animal at
Genetically Engineered Mouse Modeling facility at the Ohio State University Comprehensive
Cancer Center (OSUCCC). The founders were identified by southern blot analysis of tail DNA for the presence of hROR1 transgene using P 32 labeled hROR1 cDNA probe (fragment size and restriction enzyme used to generate the probe). Two independent founder animals identified were bred to C57BL/6 to establish founder lines that were genotyped by PCR with primers specific for hROR1 using genomic tail DNA.
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Selectivity study:
Cell lines or human PBMC cells were co-incubated with 2A2-IgG followed by secondary PE- Statistics:
For data with repeated measures, mixed effect models were used considering observational dependencies across subjects. 4 Matched samples were compared by paired t-tests. Analysis of variance (ANOVA) was used to compare means of multiple independent groups. The association between phospho SHP1 and change in cell viability was assessed by Spearman correlation test. The log-rank test was applied for analysis of animal survival study. Holm's method was employed to adjust multiplicity to control the family wise error rate at 0.05. 5 For the gene expression profiling experiment, data were normalized by RMA method and two-sample ttests were used to detect differentially expressed genes. Smoothing method was applied to improve variance estimates in the tests 6 . The expected false positive rate was controlled at 0.0005 (five false positive out of 10000 tests). 
